Current surgical management of ovarian cancer

Hematology/Oncology Clinics of North America

Volumn 26, Issue 1, 2012, Pages 93-109

  Schorge, John O ^a   Eisenhauer, Eric E ^b   Chi, Dennis S ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Interval debulking surgery; Ovarian cancer; Primary debulking surgery; Secondary debulking surgery

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; CA 125 ANTIGEN;

ABDOMINAL HYSTERECTOMY; ADJUVANT CHEMOTHERAPY; ADNEXECTOMY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYTOREDUCTIVE SURGERY; DYSGERMINOMA; EPITHELIAL OVARY CARCINOMA; GYNECOLOGIC SURGERY; HUMAN; LAPAROSCOPIC SURGERY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVARY GERM CELL TUMOR; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ROBOTICS; SALPINGOOOPHORECTOMY; TUMOR VOLUME;

FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PALLIATIVE CARE;

EID: 84855867142     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.10.004     Document Type: Review

References (78)

1. Engelen M.J., Kos H.E., Willemse P.H., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006, 106:589-598.
2. Verleye L., Vergote I., van der Zee A.G. Patterns of care in surgery for ovarian cancer in Europe. Eur J Surg Oncol 2010, 36(Suppl 1):S108-S114.
3. Carney M.E., Lancaster J.M., Ford C., et al. Apopulation-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?. Gynecol Oncol 2002, 84:36-42.
4. Chan J.K., Kapp D.S., Shin J.Y., et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol 2007, 109:1342-1350.
5. Moore R.G., McMeekin D.S., Brown A.K., et al. Anovel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009, 112:40-46.
6. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011, 117:742-746.
7. Schorge J.O., Modesitt S.C., Coleman R.L., et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010, 119:7-17.
8. Buys S.S., Partridge E., Black A., et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 2011, 305:2295-2303.
9. Fader A.N., Rose P.G. Role of surgery in ovarian carcinoma. JClin Oncol 2007, 25:2873-2883.
10. Whitney C.W., Spirtos N. Gynecologic Oncology Group surgical procedures manual 2009, Gynecologic Oncology Group, Philadelphia (PA), Available at:, Accessed October 21, 2011. http://www.gog.org.
11. Morice P., Joulie F., Camatte S., et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. JAm Coll Surg 2003, 197:198-205.
12. Powless C.A., Aletti G.D., Bakkum-Gamez J.N., et al. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol 2011, 122:536-540.
13. Cass I., Li A.J., Runowicz C.D., et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001, 80:56-61.
14. Chan J.K., Munro E.G., Cheung M.K., et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 2007, 109:12-19.
15. Young R.C., Decker D.G., Wharton J.T., et al. Staging laparotomy in early ovarian cancer. JAMA 1983, 250:3072-3076.
16. Trimbos J.B., Parmar M., Vergote I., et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. JNatl Cancer Inst 2003, 95:105-112.
17. Trimbos J.B., Vergote I., Bolis G., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. JNatl Cancer Inst 2003, 95:113-125.
18. Chan J.K., Tian C., Fleming G.F., et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol 2010, 116:301-306.
19. Chi D.S., Abu-Rustum N.R., Sonoda Y., et al. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol 2005, 192:1614-1619.
20. Liu C.S., Nagarsheth N.P., Nezhat F.R. Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer?. JMinim Invasive Gynecol 2009, 16:250-262.
21. Magrina J.F., Zanagnolo V., Noble B.N., et al. Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy. Gynecol Oncol 2011, 121:100-105.
22. Zivanovic O., Sonoda Y., Diaz J.P., et al. The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol 2008, 111:431-437.
23. Rao G.G., Skinner E., Gehrig P.A., et al. Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol 2004, 104:261-266.
24. Wingo S.N., Knowles L.M., Carrick K.S., et al. Retrospective cohort study of surgical staging for ovarian low malignant potential tumors. Am J Obstet Gynecol 2006, 194:e20-e22.
25. Houck K., Nikrui N., Duska L., et al. Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis. Obstet Gynecol 2000, 95:839-843.
26. Brown J., Sood A.K., Deavers M.T., et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?. Gynecol Oncol 2009, 113:86-90.
27. Schilder J.M., Thompson A.M., DePriest P.D., et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002, 87:1-7.
28. Rao G.G., Skinner E.N., Gehrig P.A., et al. Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol 2005, 98:263-266.
29. Zanagnolo V., Pasinetti B., Sartori E. Clinical review of 63 cases of sex cord stromal tumors. Eur J Gynaecol Oncol 2004, 25:431-438.
30. Peccatori F., Bonazzi C., Chiari S., et al. Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients. Obstet Gynecol 1995, 86:367-372.
31. Curley M.D., Garrett L.A., Schorge J.O., et al. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci 2011, 16:368-392.
32. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
33. Goldie J.H., Coldman A.J. Amathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979, 63:1727-1733.
34. Covens A.L. Acritique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000, 78:269-274.
35. Meigs J.V. Tumors of the female pelvic organs 1934, Macmillan, New York.
36. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975, 42:101-104.
37. Griffiths C.T., Parker L.M., Fuller A.F. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979, 63:235-240.
38. Hacker N.F., Berek J.S., Lagasse L.D., et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983, 61:413-420.
39. Piver M.S., Lele S.B., Marchetti D.L., et al. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. JClin Oncol 1988, 6:983-989.
40. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. NEngl J Med 2006, 354:34-43.
41. Aletti G.D., Dowdy S.C., Podratz K.C., et al. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 2006, 100:283-287.
42. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006, 103:1083-1090.
43. McCann C.K., Growdon W.B., Munro E.G., et al. Prognostic significance of splenectomy as part of initial cytoreductive surgery in ovarian cancer. Ann Surg Oncol 2011, 18(10):2912-2918.
44. Ang C., Chan K.K., Bryant A., et al. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011, 4. CD007697.
45. Aletti G.D., Dowdy S.C., Gostout B.S., et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. JAm Coll Surg 2009, 208:614-620.
46. Chi D.S., Eisenhauer E.L., Zivanovic O., et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009, 114:26-31.
47. Wimberger P., Lehmann N., Kimmig R., et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007, 106:69-74.
48. Chi D.S., Ramirez P.T., Teitcher J.B., et al. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. JClin Oncol 2007, 25:4946-4951.
49. Winter W.E., Maxwell G.L., Tian C., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. JClin Oncol 2007, 25:3621-3627.
50. Winter W.E., Maxwell G.L., Tian C., et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. JClin Oncol 2008, 26:83-89.
51. Chi D.S., Eisenhauer E.L., Lang J., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 2006, 103:559-564.
52. Rauh-Hain J.A., Growdon W.B., Rodriguez N., et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Gynecol Oncol 2011, 120:S12-S13.
53. Vergote I., Trope C.G., Amant F., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. NEngl J Med 2010, 363:943-953.
54. Thrall M.M., Goff B.A., Symons R.G., et al. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol 2011, 118:537-547.
55. Fanning J., Yacoub E., Hojat R. Laparoscopic-assisted cytoreduction for primary advanced ovarian cancer: success, morbidity and survival. Gynecol Oncol 2011, 123:47-49.
56. van der Burg M.E., van L.M., Buyse M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization forResearch and Treatment of Cancer. NEngl J Med 1995, 332:629-634.
57. Rose P.G., Nerenstone S., Brady M.F., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. NEngl J Med 2004, 351:2489-2497.
58. Hou J.Y., Kelly M.G., Yu H., et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 2007, 105:211-217.
59. Kang S., Nam B.H. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol 2009, 16:2315-2320.
60. Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006, 103:1070-1076.
61. Bristow R.E., Eisenhauer E.L., Santillan A., et al. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007, 104:480-490.
62. Dewdney S.B., Rimel B.J., Reinhart A.J., et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol 2010, 119:18-21.
63. Vergote I., Amant F., Leunen K. Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?. Gynecol Oncol 2010, 119:1-2.
64. Bristow R.E., Puri I., Chi D.S. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009, 112:265-274.
65. Bristow R.E., Peiretti M., Gerardi M., et al. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol Oncol 2009, 114:173-177.
66. Fotiou S., Aliki T., Petros Z., et al. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer. Gynecol Oncol 2009, 114:178-182.
67. Schorge J.O., Wingo S.N., Bhore R., et al. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet 2010, 108:123-127.
68. Chi D.S., McCaughty K., Diaz J.P., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006, 106:1933-1939.
69. Harter P., Du B.A., Hahmann M., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006, 13:1702-1710.
70. Fotopoulou C., Richter R., Braicu I.E., et al. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol 2011, 18:49-57.
71. Shih K.K., Chi D.S., Barakat R.R., et al. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol 2010, 117(2):330-335.
72. Shih K.K., Chi D.S., Barakat R.R., et al. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 2010, 116:364-369.
73. von Gruenigen V.E., Frasure H.E., Reidy A.M., et al. Clinical disease course during the last year in ovarian cancer. Gynecol Oncol 2003, 90:619-624.
74. Kucukmetin A., Naik R., Galaal K., et al. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database Syst Rev 2010, 7. CD007792.
75. Caceres A., Zhou Q., Iasonos A., et al. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. Gynecol Oncol 2008, 108:482-485.
76. Chi D.S., Phaeton R., Miner T.J., et al. Aprospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist 2009, 14:835-839.
77. Pothuri B., Vaidya A., Aghajanian C., et al. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol 2003, 89:306-313.
78. Ripamonti C., Bruera E. Palliative management of malignant bowel obstruction. Int J Gynecol Cancer 2002, 12:135-143.